申请人:Rhone-Poulenc Rorer Limited
公开号:US06211234B1
公开(公告)日:2001-04-03
Compounds of formula (I) are described wherein R1 is hydrogen, -(lower alkyl)q(CO2R6 or OH), —CN, —C(R7)═NOR8, NO2, —O(lower alkyl)R9, —C≡C—R10, —CR11═C(R12)(R13), —C(═O)CH2C(═O)CO2H, —CO(R14), alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, thiocarbamoyl, substituted carbamoyl, substituted thiocarbamoyl, sulphamoyl or an optionally substituted nitrogen-containing ring, m, n, o and p are independently zero or 1 and R2, R3, R4 and R5 are various groups; and physiologically acceptable salts, N-oxides and prodrugs thereof. The compounds have endothelin antagonist activity and are useful as pharmaceuticals.
式(I)的化合物描述如下,其中R1为氢,-(较低烷基)q(CO2R6或OH),—CN,—C(R7)HNOR8,NO2,—O(较低烷基)R9,—C≡C—R10,—CR11CH(R12)(R13),—C(O)CH2C(O)CO2H,—CO(R14),烷基硫醚,烷基亚砜基,烷基磺酰基,氨基甲酰基,硫代氨基甲酰基,取代的氨基甲酰基,取代的硫代氨基甲酰基,磺酰胺基或可选择取代的含氮环,m、n、o和p独立地为零或1,R2、R3、R4和R5为各种基团;以及其生理学上可接受的盐、N-氧化物和前药。这些化合物具有内皮素拮抗活性,并可用作药物。